Your browser doesn't support javascript.
loading
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
Alexander, Elizabeth; Goldberg, Lisa; Das, Anita F; Moran, Gregory J; Sandrock, Christian; Gasink, Leanne B; Spera, Patricia; Sweeney, Carolyn; Paukner, Susanne; Wicha, Wolfgang W; Gelone, Steven P; Schranz, Jennifer.
Afiliación
  • Alexander E; Nabriva Therapeutics US Inc, King of Prussia, Pennsylvania.
  • Goldberg L; Nabriva Therapeutics US Inc, King of Prussia, Pennsylvania.
  • Das AF; Das Consulting, Guerneville, California.
  • Moran GJ; Olive View-UCLA Medical Center, Los Angeles, California.
  • Sandrock C; University of California, Davis, School of Medicine, Sacramento.
  • Gasink LB; Nabriva Therapeutics US Inc, King of Prussia, Pennsylvania.
  • Spera P; Nabriva Therapeutics US Inc, King of Prussia, Pennsylvania.
  • Sweeney C; Nabriva Therapeutics US Inc, King of Prussia, Pennsylvania.
  • Paukner S; Nabriva Therapeutics GmbH, Vienna, Austria.
  • Wicha WW; Nabriva Therapeutics GmbH, Vienna, Austria.
  • Gelone SP; Nabriva Therapeutics US Inc, King of Prussia, Pennsylvania.
  • Schranz J; Nabriva Therapeutics US Inc, King of Prussia, Pennsylvania.
JAMA ; 322(17): 1661-1671, 2019 Nov 05.
Article en En | MEDLINE | ID: mdl-31560372

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: JAMA Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: JAMA Año: 2019 Tipo del documento: Article